Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Non-Current Liabilities (2022 - 2024)

Historic Total Non-Current Liabilities for Rhythm Pharmaceuticals (RYTM) over the last 3 years, with Q2 2024 value amounting to $166.8 million.

  • Rhythm Pharmaceuticals' Total Non-Current Liabilities rose 3199.12% to $166.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $166.8 million, marking a year-over-year increase of 3199.12%. This contributed to the annual value of $161.8 million for FY2023, which is 3846.46% up from last year.
  • Rhythm Pharmaceuticals' Total Non-Current Liabilities amounted to $166.8 million in Q2 2024, which was up 3199.12% from $162.5 million recorded in Q1 2024.
  • In the past 5 years, Rhythm Pharmaceuticals' Total Non-Current Liabilities registered a high of $166.8 million during Q2 2024, and its lowest value of $80.5 million during Q2 2022.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Total Non-Current Liabilities value was $126.3 million (recorded in 2023), while the average stood at $133.7 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Total Non-Current Liabilities skyrocketed by 5702.55% in 2023, and later soared by 2903.41% in 2024.
  • Quarter analysis of 3 years shows Rhythm Pharmaceuticals' Total Non-Current Liabilities stood at $116.9 million in 2022, then surged by 38.46% to $161.8 million in 2023, then rose by 3.04% to $166.8 million in 2024.
  • Its Total Non-Current Liabilities stands at $166.8 million for Q2 2024, versus $162.5 million for Q1 2024 and $161.8 million for Q4 2023.